PWR
81
6
DE
63
4
NTAP
50
-2
MCO
68
-2
GWW
74
7
EMN
43
-12
OKE
40
-5
CPB
42
12
CAH
69
5
CSX
29
2
BWA
50
2
HOG
38
3
GIS
44
-3
PEG
48
-3
AZO
63
-2
KMX
43
3
FMC
29
-11
PBI
49
3
AIZ
69
-2
EIX
39
4
PWR
81
6
DE
63
4
NTAP
50
-2
MCO
68
-2
GWW
74
7
EMN
43
-12
OKE
40
-5
CPB
42
12
CAH
69
5
CSX
29
2
BWA
50
2
HOG
38
3
GIS
44
-3
PEG
48
-3
AZO
63
-2
KMX
43
3
FMC
29
-11
PBI
49
3
AIZ
69
-2
EIX
39
4
Financhill
Back

Sarepta Therapeutics 10K Form

Buy
68

SRPT
Sarepta Therapeutics

Last Price:
$62.77
Seasonality Move:
16.21%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.9B
Cash Flow: $54M
Price / Cash Flow: 0
Annual Sales: $15.77
Price / Book: 3.96

Profitability

EPS (TTM): 2.28000
Net Income (TTM): $235.2M
Gross Margin: $1.6B
Return on Equity: 20.83%
Return on Assets: 6.73%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for SRPT is 83.22%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 29.33% of Gross Profit Margin.
  • The Research & Development expenses have been 42.30% of Revenue.
  • The Interest Expense is 7.82% of Operating Income.
  • The Net Earning history of SRPT is 12.37% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 15 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 0.74
Current Ratio: 4.2
Quick Ratio: 2.74

Price-to-Earnings

Trailing P/E Ratio: 26.67
Forward P/E Ratio: 4.51

SRPT Technical Analysis vs Fundamental Analysis

Buy
68
Sarepta Therapeutics (SRPT) is a Buy

Is Sarepta Therapeutics a Buy or a Sell?